Can FLUOROCHEM recover the margin miss from Q1?
Gujarat Fluorochemicals reports Q2 FY27 on Nov 3 with the Street watching volumes and profit leverage after Q1's revenue beat masked a significant PAT miss. Current price weakness — 14% off ATH — is betting that specialty chemicals and EV-adjacency growth can't offset cost pressures and expanding EV losses.
The Setup: Q1 Exposed the Margin Gap
Gujarat Fluorochemicals shocked the Street in August with a revenue beat but a dramatic PAT miss. Consolidated revenue of ₹1,588 Cr crushed expectations (Street preview: ₹1,395 Cr; +24% YoY growth), but net profit of ₹219 Cr fell short of the Street's ₹276 Cr view by ₹57 Cr—a 21% shortfall on profit despite a 14% revenue beat. The culprit: cost inflation in raw materials and energy, coupled with widening losses in the company's EV-related subsidiaries. This Q2 is all about whether management can recover that leverage.
~₹1,500–1,550 Cr
On-plan run-rate: Q1 was ₹1,588 Cr; growth trajectory suggests steady or slight sequential moderation with YoY growth of 20–25%.
~₹200–230 Cr
Recovery threshold: Q1 was ₹219 Cr. Street will scrutinize margin % and whether cost pressures ease or EV losses stabilize. A PAT miss of >₹30 Cr again would signal structural margin headwinds.
~20–22%
Q1 implied margin pressure despite volume growth. Watch for pass-through of input costs to customers or operational improvements.
Focus item
Expanding losses are a drag on consolidated PAT. Q2 disclosure on this sub will shape FY27 guidance credibility.
A strong Q2 would show: (1) revenue on-plan or ahead, (2) PAT recovery to ₹225–250 Cr range (i.e., margin recovery YoY and QoQ), (3) EBITDA margin stabilization above 21%, and (4) EV losses either static or itemized as a temporary investment phase. A weak Q2 would repeat Q1's pattern: revenue strength masking profit miss, EV losses expanding, and forward guidance unclear on leverage recovery. Anything below ₹210 Cr PAT would signal that cost inflation is structural, not transient.
On Track for FY27 Guidance?
The company has not issued explicit quarterly or full-year PAT guidance, but analyst consensus for FY27 points to EPS growth of ~59% and revenue growth of ~32.5%. For that to hold, H2 would need stronger profitability than H1 is showing. Q1 PAT of ₹219 Cr annualizes to ~₹876 Cr at that run-rate—below the 59% EPS growth implied. This means either Q2–Q4 margins must improve materially, or the 59% EPS growth implies a lower earnings base than Q1 suggests. Investors should press management on whether the PAT miss in Q1 was one-time (input inflation easing, EV subs stabilizing) or the new normal (requiring margin expansion elsewhere). The price is 14% off ATH despite analyst targets of ₹4,860, suggesting the market is skeptical of that leverage recovery.
What the Street Says
Since Last Quarter: Filings & Corporate Actions
Aug 27, 2026
FY26 final dividend declared; record date Sep 17. Routine shareholder return; no strategic signal.
Dividend: Final ₹3/share
Aug 27, 2026
8th AGM held Sep 24. Board re-appointed Dr. Bir Kapoor (Deputy MD) and Niraj Kishore Agnihotri (Whole-time Director). Governance routine; no major leadership change.
AGM & Annual Report (FY26)
Sep 24, 2026
Shareholders approved re-appointment of two key executives. Continuity signal on management.
AGM: Directors re-appointed
Sep 28, 2026
Window closed Oct 1, 2026 for Q2 results announcement. Standard regulatory closure; no insider activity noted.
Trading Window Closure
Oct 26, 2026
Board to convene Nov 3, 2026 to approve Q2 FY27 unaudited financial results. Result day confirmed.
Board Meeting Notice
No major M&A, pledge updates, or regulatory concerns flagged. The Scheme of Arrangement with Inox Leasing (announced in Q1) received BSE/NSE no-objection letters in July—no further update in recent filings, suggesting it is progressing as planned but not material to Q2 guidance. Insider trading window closure on Oct 1 is routine. Overall, the quarter has been quiet on corporate action; the focus is entirely on operational execution.
What to Watch on Result Day (Nov 3)
1 · Profit recovery & margin narrative
Did PAT improve QoQ or YoY? Is it ≥₹220 Cr (recovery signal) or <₹210 Cr (structural miss)? Listen for management commentary on input-cost trends: are they easing in October–November, or does the company expect ongoing inflation? A credible path to 15%+ PAT margin (vs. implied 14% now) would stabilize sentiment.
2 · EV subsidiary losses & guidance
How much PAT drag from EV-related businesses? Is it being phased out, or is it a long-term investment? If losses >₹20 Cr and no timeline to breakeven, analysts may reduce FY27 EPS estimates. Q2 disclosure (even if unaudited) on this segment is critical to FY27 credibility.
3 · FY27 full-year outlook & management tone
Does management reaffirm the implied 59% EPS growth? Or do they guide more conservatively? Any update on battery-chemicals or fluoropolymer volumes? If H2 visibility is weak or EV losses are expected to widen further, sentiment will sour despite Q1 revenue strength. A timid outlook would likely trigger analyst cuts and renewed price weakness.
FLUOROCHEM is at an inflection. Q1 showed the company can drive volume growth (+24% revenue), but profitability leverage is stuck—a ₹57 Cr PAT miss erased the celebration. The market has noticed: the stock is down 15% from its all-time high despite analyst consensus that EPS should grow 59% this year. That skepticism hinges entirely on Q2. If margins recover and management can credibly map a path to the 59% EPS growth, the analyst consensus target of ₹4,860 becomes plausible. If Q2 repeats Q1's pattern (volume beat, profit miss), expect target cuts and further downside.
Watch three things on Nov 3: (1) did PAT rebound above ₹220 Cr and margins stabilize? (2) are EV losses explained and bounded? (3) does management stand by FY27 guidance with conviction? The answers will reset the narrative from 'growth missed by execution' to either 'margin recovery underway' or 'structural cost pressure.' Current price weakness leaves room for a 15% upside to analyst targets—but Q2 profitability is the gate.
Informational and educational content only. Not investment advice.